Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
Sector news Bio Therapeutic Drugs
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
09/27Novartis strikes deal with Chinese firm to make Kymriah
RE
09/27Novartis strikes deal with Chinese firm to make Kymriah
RE
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- 2nd Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans -- U..
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/12EUROPE : European stocks shrug off trade worries as oil stocks rally
RE
09/12Galapagos, Gilead bask in $4-6 billion new drug sales hope
RE
09/12GILEAD SCIENCES : Precision BioSciences Developing Hepatitis B Therapies
DJ
09/06Gilead, Galapagos Phase 2 Filgotinib Study Meets Primary Endpoint
DJ
09/05NOVARTIS : Immunotherapy Gathers Momentum With NHS Deal -- Update
DJ
09/05NOVARTIS : Kymriah to Be Used for Cancer Patients in the U.K.
DJ
09/04Factbox - Challenges facing German pharmaceutical company Bayer
RE
08/28GILEAD SCIENCES : UK Nixes Gilead Gene Therapy Citing Cost, Casting Doubt on Oth..
DJ
08/27Pfizer's Rare-Disease Drug Results Lifts Some Rivals -- Market Mover
DJ
08/22EXACT SCIENCES : Shares Jump 26%
DJ
08/22EXACT SCIENCES : Shares Surge on Co-Promotion Deal With Pfizer
DJ
08/22SIERRA ONCOLOGY : Acquires Momelotinib From Gilead Sciences
DJ
08/16REGENERON PHARMACEUTICALS : Teva Report Positive Phase 3 Fasinumab Results
DJ
08/03Roche Drug for Brain Disease Granted European Fast-Track
DJ
08/02Regeneron Closes Up 7% After 2Q Earnings Beat -- Data Talk
DJ
08/02REGENERON PHARMACEUTICALS : Beats Earnings Estimates
DJ
07/31UNITED THERAPEUTICS : Medtronic Get FDA OK for Remodulin Implantable System
DJ
07/27JOHNSON & JOHNSON : J&J's Janssen Gets Positive CHMP Opinion for Darzalex as Fro..
DJ
07/27Amgen profit beats Street view, will not raise prices again in 2018
RE
07/26Upbeat Roche bests rival Novartis as new drugs fuel growth
RE
07/26JOHN MILLIGAN : Gilead CEO Milligan To Leave -- WSJ
DJ
07/25GILEAD SCIENCES : CEO Stepping Down -- Update
DJ
07/24GSK's two-drug HIV treatment proves itself in key tests
RE
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 56,1 M
EBIT 2018 -390 M
Net income 2018 -227 M
Finance 2018 255 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 53,3x
EV / Sales 2019 28,1x
Capitalization 3 249 M